Naqash, A. R.; Ricciuti, B.; Owen, D. H.; Florou, V.; Toi, Y.; Cherry, C.; Hafiz, M.; De Giglio, A.; Muzaffar, M.; Patel, S. H.; Sugawara, S.; Burkart, J.; Park, W.; Chiari, R.; Sugisaka, J.; Otterson, G. A.; de Lima Lopes, G.; Walker, P. R., Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5), «CANCER IMMUNOLOGY, IMMUNOTHERAPY», 2020, 69, pp. 1189 - 1189 [Scientific article]
Tateo V.; Manuzzi L.; De Giglio A.; Parisi C.; Lamberti G.; Campana D.; Pantaleo M.A., Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2020, 21, Article number: 9056 , pp. 1 - 16 [Scientific article]Open Access
De Giglio, A.; Mezquita, L.; Auclin, E.; Blanc-Durand, F.; Riudavets, M.; Caramella, C.; Martinez, G.; Benitez, J. C.; Martin-Romano, P.; El-Amarti, L.; Hendriks, L.; Ferrara, R.; Naltet, C.; Lavaud, P.; Gazzah, A.; Adam, J.; Planchard, D.; Chaput, N.; Besse, B., Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici), «CANCERS», 2020, 12, Article number: 2827 , pp. 1 - 11 [Scientific article]Open Access
Nigro, O.; Pinotti, G.; De Galitiis, F.; Di Pietro, F. R.; Giusti, R.; Filetti, M.; Bersanelli, M.; Lazzarin, A.; Bordi, P.; Catino, A.; Pizzutilo, P.; Galetta, D.; Marchetti, P.; Botticelli, A.; Scagnoli, S.; Russano, M.; Santini, D.; Torniai, M.; Berardi, R.; Ricciuti, B.; De Giglio, A.; Chiari, R.; Russo, A.; Adamo, V.; Tudini, M.; Silva, R. R.; Bolzacchini, E.; Giordano, M.; Di Marino, P.; De Tursi, M.; Rijavec, E.; Ghidini, M.; Vallini, I.; Stucci, L. S.; Tucci, M.; Pala, L.; Conforti, F.; Queirolo, P.; Tanda, E.; Spagnolo, F.; Cecchi, F.; Bracarda, S.; Macrini, S.; Santoni, M.; Battelli, N.; Fargnoli, M. C.; Porzio, G.; Tuzi, A.; Suter, M. B.; Ficorella, C.; Cortellini, A., Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study, «EUROPEAN JOURNAL OF CANCER», 2020, 134, pp. 19 - 28 [Scientific article]
Cortellini, A.; Leonetti, A.; Catino, A.; Pizzutillo, P.; Ricciuti, B.; De Giglio, A.; Chiari, R.; Bordi, P.; Santini, D.; Giusti, R.; De Tursi, M.; Brocco, D.; Zoratto, F.; Rastelli, F.; Citarella, F.; Russano, M.; Filetti, M.; Marchetti, P.; Berardi, R.; Torniai, M.; Cortinovis, D.; Sala, E.; Maggioni, C.; Follador, A.; Macerelli, M.; Nigro, O.; Tuzi, A.; Iacono, D.; Migliorino, M. R.; Banna, G.; Porzio, G.; Cannita, K.; Ferrara, M. G.; Bria, E.; Galetta, D.; Ficorella, C.; Tiseo, M., Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes, «CLINICAL & TRANSLATIONAL ONCOLOGY», 2020, 22, pp. 844 - 851 [Scientific article]
Naqash, A. R.; Ricciuti, B.; Owen, D. H.; Florou, V.; Toi, Y.; Cherry, C.; Hafiz, M.; De Giglio, A.; Muzaffar, M.; Patel, S. H.; Sugawara, S.; Burkart, J.; Park, W.; Chiari, R.; Sugisaka, J.; Otterson, G. A.; de Lima Lopes, G.; Walker, P. R., Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort, «CANCER IMMUNOLOGY, IMMUNOTHERAPY», 2020, 69, pp. 1177 - 1187 [Scientific article]
De Giglio, A.; Lamberti, G.; Facchinetti, F.; Genova, C.; Andrini, E.; Dal Bello, M. G.; Tiseo, M.; Metro, G.; Chiari, R.; Ricciuti, B., Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib, «CLINICAL LUNG CANCER», 2020, 21, pp. 478 - 487 [Scientific article]
Cortellini, A.; Bersanelli, M.; Buti, S.; Cannita, K.; Santini, D.; Perrone, F.; Giusti, R.; Tiseo, M.; Michiara, M.; Di Marino, P.; Tinari, N.; De Tursi, M.; Zoratto, F.; Veltri, E.; Marconcini, R.; Malorgio, F.; Russano, M.; Anesi, C.; Zeppola, T.; Filetti, M.; Marchetti, P.; Botticelli, A.; Antonini Cappellini, G. C.; De Galitiis, F.; Vitale, M. G.; Rastelli, F.; Pergolesi, F.; Berardi, R.; Rinaldi, S.; Tudini, M.; Silva, R. R.; Pireddu, A.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Iacono, D.; Gelibter, A.; Occhipinti, M. A.; Parisi, A.; Porzio, G.; Fargnoli, M. C.; Ascierto, P. A.; Ficorella, C.; Natoli, C., A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2019, 7, Article number: 57 , pp. 1 - 11 [Scientific article]Open Access
de Giglio, A.; Nuvola, G.; Gustavo Dall'Olio, F., Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies, «TRANSLATIONAL CANCER RESEARCH», 2019, 8, pp. 18 - 23 [Scientific article]Open Access
Ricciuti, B.; Genova, C.; De Giglio, A.; Bassanelli, M.; Dal Bello, M. G.; Metro, G.; Brambilla, M.; Baglivo, S.; Grossi, F.; Chiari, R., Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2019, 145, pp. 479 - 485 [Scientific article]
Boni, A.; Cochetti, G.; Sidoni, A.; Bellezza, G.; Lepri, E.; De Giglio, A.; Turco, M.; Vermandois, J. A. R. D.; Zingaro, M. D.; Cirocchi, R.; Mearini, E., Primary angiosarcoma of the kidney: Case report and comprehensive literature review, «OPEN MEDICINE», 2019, 14, pp. 443 - 455 [Scientific article]Open Access
Verzoni, E.; Carteni, G.; Cortesi, E.; Giannarelli, D.; De Giglio, A.; Sabbatini, R.; Buti, S.; Rossetti, S.; Cognetti, F.; Rastelli, F.; Sobrero, A.; Turci, D.; Sternberg, C. N.; Porta, C.; Cappuzzo, F.; Tortora, G.; Tassinari, D.; Panni, S.; Pazzola, A.; Surico, G.; Raimondi, A.; De Giorgi, U.; Procopio, G., Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2019, 7, Article number: 99 , pp. 1 - 9 [Scientific article]Open Access
Abu-Sbeih, H.; Ali, F. S.; Naqash, A. R.; Owen, D. H.; Patel, S.; Otterson, G. A.; Kendra, K.; Ricciuti, B.; Chiari, R.; De Giglio, A.; Sleiman, J.; Funchain, P.; Wills, B.; Zhang, J.; Naidoo, J.; Philpott, J.; Gao, J.; Subudhi, S. K.; Wang, Y., Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis, «JOURNAL OF CLINICAL ONCOLOGY», 2019, 37, pp. 2738 - 2745 [Scientific article]Open Access
Ricciuti, B.; Genova, C.; Bassanelli, M.; De Giglio, A.; Brambilla, M.; Metro, G.; Baglivo, S.; Dal Bello, M. G.; Ceribelli, A.; Grossi, F.; Chiari, R., Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression, «CLINICAL LUNG CANCER», 2019, 20, pp. 178 - 185 [Scientific article]
Ricciuti, B.; Baglivo, S.; De Giglio, A.; Chiari, R., Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience, «THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE», 2018, 12, Article number: 1753466618808659 , pp. 1 - 13 [Scientific article]Open Access
